Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06458192 · ClinicalTrials.gov registry record · NA

Adaptive Messaging to Support Depression Self-Management

A NA study of Depression, sponsored by Northwestern University.

Active
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT06458192 is a NA study of Depression that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 100 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06458192, a NA study of Depression, is active but no longer recruiting, sponsored by Northwestern University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This is a pilot randomized controlled trial of an adaptive 8-week text messaging intervention for depression self-management. Among 100 individuals with elevated depression symptoms, the investigators will compare the effects of 8 weeks of the adaptive text messaging intervention (n=40) to 8 weeks of a non-adaptive text messaging intervention (n=40), and 8 weeks of a psychoeducation-only intervention (n=20). The investigators will include a 6-month post-treatment follow-up to verify that treatment gains are maintained. Both messaging arms will receive 8 weeks of daily text messaging. Messages will prompt learning and applying cognitive and behavioral self-management strategies. Whereas the non-adaptive messaging system will randomly select daily messaging styles (representing a variety of self-management strategies and message tones), the adaptive messaging system will apply reinforcement learning to select daily messaging styles to maximize user engagement. Text messages will also be used to solicit feedback such as message ratings to inform the reinforcement learning algorithm (if applicable). The psychoeducation control group will receive a few brief text messages per week providing weblinks to access psychoeducation information. The investigators will recruit participants through digital methods (e.g., advertising on social media platforms like Facebook and Instagram). Administration of study measures will occur at baseline, weeks 4 and 8, and 3-month and 6-month follow-up. The primary outcomes is depression symptom severity (PHQ-9). Secondary outcomes are: anxiety severity (GAD-7) and suicidality (DSI-SS). Using an Intention to Treat paradigm, the investigators will test our hypothesis that: H1: Relative to the psychoeducation-only control, messaging interventions will reduce depression (H1a) and anxiety and suicidal ideation (H1b). H2: Relative to non-adaptive messaging, adaptive messaging will reduce depression (H1a) and anxiety and suicidality (H2b). H

Conditions Studied

Interventions

  • BEHAVIORAL Adaptive Messaging Intervention
  • BEHAVIORAL Non-Adaptive Messaging Intervention
  • BEHAVIORAL Psychoeducation-Only Control

Study Locations (1)

Illinois

  • Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2025-01-13
Est. Completion 2025-12-18
Phase NA

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT06458192

The ClinicalTrials.gov registry entry for NCT06458192 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (87% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Adaptive Messaging Intervention is the first listed.

NCT06458192 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06458192 about?

NCT06458192 is a clinical study titled "Adaptive Messaging to Support Depression Self-Management". This is a pilot randomized controlled trial of an adaptive 8-week text messaging intervention for depression self-management. Among 100 individuals with elevated depression symptoms, the investigators will compare the effects of 8 weeks of the adaptive text messaging intervention (n=40) to 8 weeks o...

What is the current status of trial NCT06458192?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2025-01-13. Estimated completion is 2025-12-18.

What conditions does trial NCT06458192 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT06458192?

The interventions under investigation include: Adaptive Messaging Intervention (BEHAVIORAL), Non-Adaptive Messaging Intervention (BEHAVIORAL), Psychoeducation-Only Control (BEHAVIORAL).

Who is sponsoring clinical trial NCT06458192?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06458192 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.